Six years ago, Congress passed the STOCK Act, which for the first time made members of Congress liable for insider trading, just like any other investor. On Wednesday, the Justice Department issued the very first indictment under that law when it arrested Representative Chris Collins, Trump’s earliest supporter in Congress, and accused him of sharing inside information about an Australian pharmaceutical company with his son and other investors.

Last year, Collins allegedly learned, before the public did, about the failure of a clinical trial for a multiple sclerosis drug by Innate Immunotherapeutic. He told Cameron Collins, his son and a fellow shareholder, who dumped his stock. Cameron then distributed the information to at least six other investors, who also sold the stock before news broke about the failed trial, dropping the stock price by 92 percent. All told, the defendants and their friends avoided over $768,000 in losses, according to the indictment.

The STOCK Act was intended to prevent members of Congress, who have access to all kinds of non-public information, from using their knowledge to make money for themselves and others. But Collins came by his information in a different, almost unbelievable way: He was on the board of directors of Innate Immunotherapeutics while also serving in Congress. Collins also held 16.8 percent of the company’s stock, and he was the company’s unofficial tout on Capitol Hill, getting at least six colleagues—including, at one point, former Health and Human Services Secretary Tom Price—to buy shares.

Meanwhile, Collins sits on the House Energy and Commerce Committee’s health subcommittee, a position that gives him policymaking responsibilities over the pharmaceutical industry. As many Americans are learning for the first time today, there is no law prohibiting a congressman from serving as a corporate board member—even if that congressman specializes in policymaking that covers that corporation’s industry.

The details in the indictment are comical in the retelling of such naked corruption. When Collins learned about the failure of the multiple sclerosis drug trial, Innate Immunotherapeutics had halted trading on its shares at the Australian Stock Exchange, a routine circumstance when a company receives important news that they will later make public. But the U.S. over-the-counter market did not stop trading Innate, giving insiders the chance to financially benefit.